ClinicaliQ Trial Snapshot
- A Phase 1/2a Study of WVE-007 in Adults Living With Overweight or Obesity — Recruiting • Phase I / Phase II • Diabetes / Metabolic • NCT06842186.
- WVE-007 is a new injectable weight-loss drug being tested for safety and effectiveness in overweight and obese adults, with and without type 2 diabetes.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
The purpose of this study is to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of ascending doses of WVE-007 when administered subcutaneously (SC) . Part A is a single ascending dose study in adults living with overweight and obesity. The Part B of the study is a repeat dose administration in adult with obesity, with or without Type 2 Diabetes (T2D and non-T2D, respectively). In addition, Part B includes two dose groups that will receive WVE-007 and tirzepatide in adults living with obesity and T2D. Conditions: Overweight and Obesity Interventions:…